Cardiometabolic diseases are the number one cause of death in Australia and globally.¹ An estimated 646,000 years of healthy life have been lost in 2018 due to all forms of cardiovascular disease,² with these numbers continuing to increase at an alarming rate.³ 

The regulatory network of cardiometabolic dysfunction has a distinct architecture, with multi-system drivers throughout specific organs and organ systems, cells, and the genome. Cross-talk between the metabolome and the microbiome is part of this network, communicating via secondary metabolites such as Trimethylamine N-oxide (TMAO), secondary bile acids, short-chain fatty acids, and aromatic amino acids. 

Innovative cardiometabolic plasma markers can detect disruptions to the metabolome and microbiome years before clinical manifestation of disease. The confirmation of prodromal stages in dysfunction suggests an opportunity for early therapeutic intervention and even prevention.

The seminar will discuss:

• How specific herbs and nutrients are metabolised and their corresponding key target pathways

• The role of secondary metabolites and the microbiome in cardiometabolic health

• Identification of subtle nuances in pathology markers to determine cardiometabolic risk at various stages of dysfunction

• Clinical presentations and recognition of early warning signs of dysfunction

References

1. CSIRO Nutrition & Health. Cardiometabolic Health. n.d. Retrieved from: https://research.csiro.au/nutritionandhealth/research-groups/nutrition-and-health-substantiation/our-science/cardiometabolic-health/
2. Australian Institute of Health & Welfare. Heart, stroke and vascular disease-Australian facts. 2021. Retrieved from: https://www.aihw.gov.au/reports/heart-stroke-vascular-diseases/hsvd-facts/contents/impacts/burden-of-cardiovascular-disease
3. Roth GA et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020; 76(25): 2982-3021. doi: 10.1016/j.jacc.2020.1101